Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Outlook Therapeutics (OTLK) over the last 8 years, with Q4 2025 value amounting to $49.2 million.

  • Outlook Therapeutics' Total Non-Current Liabilities rose 156.26% to $49.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $49.2 million, marking a year-over-year increase of 156.26%. This contributed to the annual value of $46.0 million for FY2025, which is N/A changed from last year.
  • Latest data reveals that Outlook Therapeutics reported Total Non-Current Liabilities of $49.2 million as of Q4 2025, which was up 156.26% from $46.0 million recorded in Q3 2025.
  • Outlook Therapeutics' Total Non-Current Liabilities' 5-year high stood at $52.1 million during Q2 2025, with a 5-year trough of $46.0 million in Q3 2025.